For the year ending 2025-12-31, MREO had -$30,664K decrease in cash & cash equivalents over the period. -$30,991K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -41,878 |
| Share-based compensation | 7,598 |
| Depreciation | 157 |
| Amortization of intangible assets | 465 |
| Amortization of operating lease right-of-use assets | 527 |
| Change in fair value of warrants | -805 |
| Non-cash interest income | 104 |
| Non-cash interest expense | 228 |
| Foreign currency transaction loss/(gain) | -6,344 |
| Other income | 300 |
| Non-cash consideration, milestone payment | 0 |
| Prepaid expenses and other current assets | 84 |
| Research and development incentives receivable | -1,396 |
| Accounts payable | -1,378 |
| Accrued expenses and other liabilities | -2,394 |
| Operating lease liabilities | -743 |
| Net cash used in operating activities | -30,971 |
| Purchase of intangible assets | 300 |
| Purchase of property and equipment | 20 |
| Proceeds from out-licensing | 300 |
| Net cash used in investing activities | -20 |
| Proceeds from exercise of warrants | 487 |
| Proceeds from issuance of ordinary shares | 39 |
| Transaction costs on issuance of ordinary shares | 199 |
| Net cash provided by financing activities | 327 |
| (decrease)/increase in cash and cash equivalents | -30,664 |
| Cash and cash equivalents at january 1 | 69,802 |
| Effect of exchange rate changes | 1,854 |
| Cash and cash equivalents at december 31 | 40,992 |
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)